<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04433104</url>
  </required_header>
  <id_info>
    <org_study_id>VinmecISC1916</org_study_id>
    <nct_id>NCT04433104</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Allogeneic Human Umbilical Cord-derived Mesenchymal Stem/Stromal Cells for Chronic Obstructive Pulmonary Disease (COPD): Study Protocol for a Matched Case-control, Phase I/II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vinmec Research Institute of Stem Cell and Gene Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vinmec Research Institute of Stem Cell and Gene Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to investigate the safety and potential therapeutic efficacy of allogeneic&#xD;
      administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary intervention in&#xD;
      combination with standard COPD medication treatments in patients with moderate-to-severe COPD&#xD;
      based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 and Vietnam&#xD;
      Ministry of Health's guidelines&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this trial is to investigate the safety and potential therapeutic efficacy of&#xD;
      allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary&#xD;
      intervention in combination with standard COPD medication treatments in patients with&#xD;
      moderate-to-severe COPD based on the Global Initiative for Chronic Obstructive Lung Disease&#xD;
      (GOLD) 2019 and Vietnam Ministry of Health's guidelines. This matched case-control phase I/II&#xD;
      trial is conducted at Vinmec Times City International Hospital, Hanoi, Vietnam between June&#xD;
      2020 and December 2021. In this study, 40 patients will be enrolled and assigned into two&#xD;
      age-, gender- and COPD condition-matched groups, including a UC-MSC group and a control&#xD;
      group. Both groups will receive standard COPD medication treatment based on the GOLD 2019&#xD;
      guidelines and the Vietnam Ministry of Health protocol. The UC-MSC group will receive two&#xD;
      doses of thawed UC-MSC product with an intervention interval of 3 months. The primary outcome&#xD;
      measures will include the incidence of prespecified administrationassociated adverse events&#xD;
      (AEs) and serious adverse events (SAEs). The efficacy will be evaluated based on the absolute&#xD;
      changes in the number of admissions, arterial blood gas analysis, lung function and lung&#xD;
      fibrosis via CT scan and chest X-ray. The clinical evaluation will be conducted at baseline&#xD;
      and 3, 6, and 12 months post&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and serious adverse events</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>To assess safety, the number of AEs or SAEs during stem cell administration (72 h) at 3 months, 6 months, and 12 months after discharge will be evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using Georges Respiratory Questionnaire</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Georges Respiratory Questionnaire has scores range from 0 to 100, with higher scores indicating more limitations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest CT</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Changes of the lung fibrosis on chest CT at 6 months, and 12 months compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood gas analysis (pH)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>arterial blood gas analysis (pH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood gas analysis (PaO2)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>arterial blood gas analysis (PaO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood gas analysis (PaCO2)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>arterial blood gas analysis (PaCO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood gas analysis (BE)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>arterial blood gas analysis (BE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood gas analysis (HCO3-)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>arterial blood gas analysis (HCO3-)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory functions (FEV1)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Respiratory functions (FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory functions (FEV1/FVC)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Respiratory functions (FEV1/FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory functions (VC)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Respiratory functions (VC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory functions (TLC)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Respiratory functions (TLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory functions (RV)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Respiratory functions (RV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory functions (DLCO)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Respiratory functions (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory functions (DLNO/DLCO)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Respiratory functions (DLNO/DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory response (CRP)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>inflammatory response (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory response (Pro-BNP)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>inflammatory response (Pro-BNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory response (Troponin-T)</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>inflammatory response (Troponin-T)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cytokine analysis from patients' plasma</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>cytokine analysis from patients' plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified medical research council</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>modified medical research council (mMRC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Treatment (UC-MSC trasnplatation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>drug therapy according to Vietnamese MOHS procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord Mesenchymal Stem Cells transplantation</intervention_name>
    <description>Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval</description>
    <arm_group_label>Treatment (UC-MSC trasnplatation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drug therapy according to Vietnamese MOHS procedure</intervention_name>
    <description>Salbutamol, Terbutaline</description>
    <arm_group_label>Treatment (UC-MSC trasnplatation)</arm_group_label>
    <arm_group_label>control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with COPD with stage B, C, or D according to GOLD 2019.&#xD;
&#xD;
          -  Age between 40-75 years old.&#xD;
&#xD;
          -  Both genders.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoker or less than 6 months of smoking cessation time.&#xD;
&#xD;
          -  Asthma and other pulmonary-related diseases and injuries (including lung tuberculosis,&#xD;
             restrictive lung disease, idiopathic pulmonary fibrosis, or lung cancer).&#xD;
&#xD;
          -  Acute and/or active infection.&#xD;
&#xD;
          -  Cancer.&#xD;
&#xD;
          -  Patients with complex cardiovascular diseases (including valvular heart disease,&#xD;
             cardiomyopathy, arrhythmia, congenital heart disease, hypertrophy syndrome).&#xD;
&#xD;
          -  Liver and kidney failure.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Patients with life expectancy less than 6 months due to concomitant illness.&#xD;
&#xD;
          -  Under immunosuppressive treatment within 8 weeks of the first screening visit.&#xD;
&#xD;
          -  Patient diagnosed diabetes with HbA1C&gt;7%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duc Minh Hoang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vinmec Research Institute of Stem Cell and Gene Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duc Minh Hoang, PhD</last_name>
    <phone>(+84) 909 743 101</phone>
    <email>v.duchm3@vinmec.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anh Hai Nguyen, MD., PhD</last_name>
    <phone>(+84)968863668</phone>
    <email>haianhnguyenbm@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vinmec International Hospital Times City</name>
      <address>
        <city>Hà Nội</city>
        <state>Hanoi</state>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anh Hai Nguyen, MD, PhD</last_name>
      <phone>(+84)968863668</phone>
      <email>haianhnguyenbm@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <results_reference>
    <citation>Ribeiro-Paes JT, Bilaqui A, Greco OT, Ruiz MA, Marcelino MY, Stessuk T, de Faria CA, Lago MR. Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. Int J Chron Obstruct Pulmon Dis. 2011 Jan 1;6:63-71. doi: 10.2147/COPD.S15292.</citation>
    <PMID>21311694</PMID>
  </results_reference>
  <results_reference>
    <citation>Stessuk T, Ruiz MA, Greco OT, Bilaqui A, Ribeiro-Paes MJ, Ribeiro-Paes JT. Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years. Rev Bras Hematol Hemoter. 2013;35(5):352-7. doi: 10.5581/1516-8484.20130113.</citation>
    <PMID>24255620</PMID>
  </results_reference>
  <results_reference>
    <citation>Stolk J, Broekman W, Mauad T, Zwaginga JJ, Roelofs H, Fibbe WE, Oostendorp J, Bajema I, Versteegh MI, Taube C, Hiemstra PS. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM. 2016 May;109(5):331-6. doi: 10.1093/qjmed/hcw001. Epub 2016 Jan 27.</citation>
    <PMID>26819296</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>umbilical cord mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

